Pipeline Molecules1

23

Total Molecules

Phase I: 22 molecules

Phase II: 7 molecules

Phase III: 3 molecules

These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Make selections below to learn more.

Click to Expand

Tumor Types
Pipeline Molecules Explorer | BioOncology

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase I

  • Breast
  • Solid Tumor

Anti-CD40 MAb

(RG7876)

 

  • Solid Tumor

Anti-MUC16 TDC

(RG7882)a

 

  • Gastrointestinal
  • Gynecologic

Anti-FAP-IL2v FP

(RG7461)

 

  • Genitourinary
  • Solid Tumor

Anti-TIGIT MAb

(MTIG7192A, RG6058)

 

  • Solid Tumor

BET inhibitor

(TEN-010, RG6146)b

 

  • Hematologic
  • Solid Tumor

CD20 CD3 TCB

(RG6026)

 

  • Hematologic

CD20 CD3 TCB

(RG7828)

 

  • Hematologic

Cergutuzumab amunaleukin (anti–CEA-IL2v)

(RG7813)

 

  • Solid Tumor

ChK1 inhibitor

(GDC-0575, RG7741)c

 

  • Solid Tumor

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)d

 

  • Gastrointestinal

Emactuzumab (anti–CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

FAP-DR5 biMAb

(RG7386)

 

  • Solid Tumor

NME ADC

(RG7986)a

 

  • Hematologic

Pan-RAF inhibitor

(RG6185)e

 

  • Solid Tumor

Personalized Cancer Vaccine

(RG6180)

 

  • Solid Tumor

PI3K inhibitor

(RG6114, GDC-0077)

 

  • Breast
  • Solid Tumor

Selective estrogen receptor degrader (SERD [2])

(GDC-0927/SRN-927, RG6047)f

 

  • Breast

Vanucizumab (anti–ANG2-VEGF biMAb)

(RG7221)

 

  • Solid Tumor

Phase II

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Breast
  • Solid Tumor

Codrituzumab (anti–glypican-3 MAb)

(GC33, RG7686)d

 

  • Gastrointestinal

Emactuzumab (anti–CSF-1R MAb)

(RG7155)

 

  • Solid Tumor

Vanucizumab (anti–ANG2‐VEGF biMAb)

(RG7221)

 

  • Gastrointestinal

Phase III

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Breast
  • Solid Tumor

aDeveloped in collaboration with Seattle Genetics. bTensha acquisition. cDeveloped in collaboration with Array BioPharma. dDeveloped in collaboration with Chugai. eIn collaboration with Hanmi Pharmaceuticals. fSeragon acquisition.

Reference

  1. Roche half-year results 2017 presentation. https://www.roche.com/dam/jcr:35ee4c5e-cb3d-49a5-9893-78d9757cef02/en/irp170727.pdf. Accessed September 12, 2017.